CBD Oil UK: Novel Food Status, Legality & What to Look For

About the author...

Will founded Supermushrooms after digging into the research behind mushroom and nootropic supplements. Every pick is checked against clinical dosing, extract standardisation, and real buyer reviews, and each star rating starts from a product's real Amazon score before being adjusted for formulation quality. Read more about how ratings are calculated.

No CBD food or supplement product has completed the UK's novel food authorisation process. As of mid-2026 every CBD oil, capsule, and gummy sold in Great Britain is on sale ahead of formal approval, tolerated under enforcement discretion rather than sold under a legal green light, while the first three applications work through a stalled review that regulators are now targeting for a decision around autumn 2026.

That is a strange position for a product this mainstream. CBD is stocked in high street pharmacies, health food shops, and supermarkets across the UK, and industry estimates put the number of regular UK users in the millions. None of that commercial normality changes its regulatory status. CBD extracted for food or supplement use has been classified as a novel food since 2019, and the authorisation process that would formally clear it for sale has dragged on for years without reaching a conclusion.

This guide sets out what novel food status actually means for CBD specifically, where the FSA's authorisation process stands right now, and what to check on a label or product page before buying. For specific product recommendations checked against the FSA's public list, see our Best CBD Oil UK review. This guide is here first to explain the regulatory reality so you can make an informed choice about what to buy and from whom.

Key Takeaways (TL;DR)

• No CBD product is currently authorised as a novel food in Great Britain; the FSA confirmed this remains the case as of June 2026.
• Three lead applications, RP07, RP350, and RP427, cleared the FSA's own safety assessment and are awaiting a decision now targeted for autumn 2026.
• That decision is stalled by a four-nations alignment requirement: Food Standards Scotland is running its own consultation before UK ministers can act.
• Products sold today rely on enforcement discretion, not legal authorisation. Only buy items listed on the FSA's public CBD list.
• The FSA's advisory maximum intake is 10mg of CBD per day for healthy adults, cut down from 70mg in 2023.
• UK law caps THC (and other controlled cannabinoids) at 1mg per product container, not by daily dose. Do not assume "THC-free" without a lab result.
• A widely cited study found major mislabeling across online CBD extracts, so ask for a certificate of analysis before buying.

What "Novel Food" Status Actually Means for CBD

The UK's novel food framework, the retained version of EU Regulation 2015/2283 administered by the Food Standards Agency, requires pre-market authorisation for any food or ingredient not consumed to a significant degree in the UK or EU before 15 May 1997. We cover the mechanics of that framework in detail in our Turkey Tail regulatory guide, since the same rule governs several restricted mushroom ingredients.

CBD's situation differs in one important respect from Turkey Tail or Cordyceps militaris. Hemp itself has a long European food history, but CBD extracted and concentrated specifically for consumption is a newer commercial product, and the FSA determined in 2019 that CBD extracts fall under novel food rules regardless of hemp's own history. Every CBD food and supplement product on the UK market, whatever its concentration or delivery format, therefore requires its own authorisation before it can legally be sold.

It is worth separating this from a different, better-known CBD product. Epidyolex, a purified CBD oral solution, is licensed by the MHRA as a prescription-only medicine for certain severe childhood epilepsies including Dravet and Lennox-Gastaut syndromes. That licensing sits under medicines regulation, not novel food rules, and has nothing to do with the food-supplement CBD sold in shops. The pharmaceutical route and the food route are entirely separate processes with separate evidentiary bars, and Epidyolex being licensed does not mean any wellness CBD oil is authorised.

Where Authorisation Currently Stands

The FSA opened its industry-wide CBD novel food process in 2021, inviting companies to submit safety dossiers by a validation deadline. Several thousand applications were submitted; the great majority remain in early-stage assessment or have been withdrawn. Progress toward an actual authorisation has been slow and uneven.

Three applications, referred to as RP07, RP350, and RP427, became the first to clear the FSA's Advisory Committee on Novel Foods and Processes safety assessment. They cover synthetic cannabidiol, a CBD isolate, and an isolated CBD product derived from hemp, all specified at 98% purity or higher. In late August 2025 the FSA opened a public consultation on a draft recommendation to authorise these three, proposing a 10mg-per-day intake cap and a set of mandatory warning labels covering under-18s, pregnancy and breastfeeding, and anyone on medication or immunosuppressed. That consultation closed on 20 November 2025.

Authorisation has not followed. Because food standards policy operates on a four-nations basis, a GB-wide authorisation needs sign-off that accounts for Scotland's position as well as England, Wales, and Northern Ireland's. Food Standards Scotland launched its own consultation on the same three applications in early 2026, running separately from the FSA's already-closed process. Both regulators have said an autumn 2026 decision remains achievable, though the FSA has acknowledged that cross-nation alignment could still push the timeline further out. There is no confirmed date, and this has already slipped more than once.

If and when RP07, RP350, or RP427 does clear ministerial approval, the authorisation attaches to that specific ingredient specification rather than to a single brand. Any company selling a product that matches an authorised specification would then be able to market it as a properly authorised novel food. Until that happens, nothing sold as CBD oil, capsules, or gummies in the UK carries that status.

What This Means If You're Buying CBD Today

The practical reality is a large, functioning market operating ahead of formal legal clearance. The FSA has not ordered a blanket removal of CBD products from UK shelves. Instead, it maintains a public list of products linked to a credible novel food application, and has advised local authorities to treat inclusion on that list as evidence a seller is moving toward compliance when setting enforcement priorities. Products that are not listed, or that have been marked "Removed," are ones the FSA has explicitly said should come off the market.

That list is not small. Reporting on the FSA's own figures has put the total close to 12,000 individual product entries at points during the process, and the FSA closed it to new submissions once existing entries had been through initial checks. Being on the list is not the same as being authorised. It only means the seller has an application in the system and has not been flagged for removal. Treat it as a floor, not a guarantee of quality or full regulatory compliance.

The underlying mechanism, an ingredient still working through novel food authorisation, is the same one covered in our guides to Turkey Tail and Cordyceps militaris, but the practical reality is nothing alike. Those mushrooms survive on a handful of overseas listings in marketplace gaps. CBD is a mainstream, freely available UK industry worth hundreds of millions of pounds, sold openly in pharmacies, supermarkets, and online under official FSA tolerance while its formal authorisation works through a slow, multi-year process.

What to Check Before You Buy

Is It on the FSA's Public List?

Before buying, search the product or brand name against the FSA's public list of CBD products linked to novel food applications, published at data.food.gov.uk. If a product is not there, or is marked "Removed," it falls outside the current enforcement tolerance entirely. This single check filters out a meaningful share of lower-quality or fly-by-night sellers, since staying on the list requires an active, ongoing application.

THC Content and the Legal Limit

The relevant UK control on THC is a legal one, not an FSA food-safety figure. Under the Misuse of Drugs Regulations 2001, a CBD product can be sold without a Home Office controlled-drugs licence only if the entire container holds no more than 1mg of THC (or other controlled cannabinoids), regardless of the product's overall size or CBD strength. This matters because CBD extracted from hemp typically carries trace THC alongside it, and "THC-free" is a marketing claim, not a guaranteed lab result. Whether a product actually sits under that 1mg-per-container threshold is confirmed only by a stated lab result, not by a bare "THC-free" label.

That low starting THC content isn't an accident. UK-grown hemp must come from Home Office-licensed cultivation using varieties on the approved industrial hemp list, bred specifically to keep THC content low in the growing crop. Imported hemp extract is expected to meet an equivalent standard. A product's raw material starting point and its finished-product testing are two separate checks, and a reputable brand can usually speak to both.

Certificates of Analysis and Third-Party Testing

A widely cited 2017 study tested 84 CBD products bought online in the US and found that only around a third were accurately labelled within a reasonable margin of their stated CBD content, with some containing meaningfully less CBD than claimed and others containing detectable THC that was not disclosed on the label.¹ The UK market has tightened since, partly because of FSA pressure, but the underlying lesson holds: label claims for CBD content and THC content are not reliably accurate without independent verification. Ask for a current batch-specific certificate of analysis from an accredited third-party lab, not a generic marketing document, and check that the batch number matches what you actually receive.

If you'd rather skip checking all of this yourself, our Best CBD Oil UK review already applies these three checks, FSA-list presence, THC verification, and a workable CBD dose, to six specific products.

What the Evidence Actually Shows

CBD's clinical evidence base is genuinely strong in one narrow area and considerably thinner everywhere else it gets marketed for. It is worth being precise about which claim the research actually supports.

The strongest evidence is in severe, treatment-resistant childhood epilepsy. A randomised, placebo-controlled trial of CBD in Dravet syndrome found the median monthly convulsive seizure rate fell from 12.4 to 5.9 with CBD, compared with 14.9 to 14.1 on placebo, though the CBD group also showed more gastrointestinal side effects, fatigue, and abnormal liver function tests.² That trial underpins Epidyolex's prescription licensing, and it used doses around 20mg per kilogram of bodyweight daily, vastly higher than the FSA's 10mg total daily guideline for food-supplement CBD.

Anxiety is the claim most commonly attached to over-the-counter CBD oil, and the evidence is real but narrower than the marketing suggests. A small randomised trial found a single 600mg dose of CBD reduced anxiety during a simulated public-speaking task in people with social anxiety disorder, bringing their response closer to that of anxiety-free controls.³ That is a single high dose under lab conditions, not a daily 10mg-or-under supplement regimen taken over weeks, and the two are not directly comparable. Evidence for sleep is weaker still: a large retrospective case series found most patients reported improved sleep scores after starting CBD, but the study was an uncontrolled chart review rather than a randomised trial, which limits how much weight the result can bear.⁴

Safety is the other side of this that a buying guide has to take seriously. CBD is metabolised through liver enzymes that also process a wide range of common medications, including some blood thinners, antiepileptics, and immunosuppressants, and a pharmacological review of adverse event and interaction data found meaningful potential for drug interactions at supplement-relevant doses, alongside signals of liver enzyme changes at higher intakes.⁵ This is precisely why the FSA's proposed warning labels single out anyone on medication, and why its own consumer guidance flags long-term higher-dose use as a factor in potential liver and thyroid effects. None of this makes CBD unsafe for most healthy adults at low doses, but it does mean the "natural, therefore harmless" framing some sellers use is not supported by the pharmacology.

CBD Alternatives With Established Legal Status

If the regulatory uncertainty around CBD is a dealbreaker, several ingredients aimed at similar goals, calm, sleep, and stress resilience, carry no novel food question at all and have their own clinical evidence bases.

For stress and anxious tension specifically, Ashwagandha has a considerably larger randomised trial base than CBD in this exact use case, with consistent reductions in perceived stress and cortisol across multiple studies.

For a calmer, more alert state without sedation, L-Theanine has a well-established mechanism through alpha-brainwave activity and a strong safety record at standard doses.

For sleep quality and the physical side of stress, Magnesium Glycinate addresses a genuinely common UK dietary shortfall with a much larger and more consistent evidence base than CBD's sleep data currently offers.

None of these carries CBD's authorisation uncertainty, because none of them is classified as a novel food in the UK. That is a genuine practical advantage independent of how their evidence compares.

FAQ

Is CBD oil actually illegal in the UK?

Not in the sense of a criminal prohibition, and not in the sense that it has been ordered off shelves. It is an unauthorised novel food, meaning it has not completed the pre-market safety authorisation the law requires before it can be legally sold as a food or supplement. The FSA has chosen enforcement discretion over a blanket removal, maintaining a public list of products it is not currently prioritising for enforcement action while their applications remain active. That is a genuinely different position from either full legality or a ban.

Has any CBD product ever been authorised in the UK?

No food-supplement CBD product has been authorised as of mid-2026. Three applications, RP07, RP350, and RP427, cleared the FSA's own safety assessment and went through public consultation in late 2025, but ministerial sign-off has not followed, partly because Food Standards Scotland is running a separate consultation that needs to conclude first under the four-nations alignment requirement. Epidyolex, a purified CBD medicine for severe childhood epilepsy, is separately licensed by the MHRA as a prescription drug, which is a different regulatory pathway entirely and not evidence that any wellness CBD product is authorised.

How much CBD is safe to take?

The FSA's current advisory maximum is 10mg of CBD per day for healthy adults, revised down from an earlier 70mg guideline in October 2023 after a reassessment of the safety data. This is advisory rather than a legal limit, but products recommending doses well above it are out of step with the regulator's own current position. Anyone under 18, pregnant, breastfeeding, trying to conceive, on regular medication, or immunosuppressed is advised to avoid CBD altogether given the current gaps in safety data for those groups.

Is CBD safe to take with other medications?

Not automatically. CBD is metabolised through liver enzymes that also process a range of common prescription drugs, and a review of adverse event and interaction data identified meaningful potential for drug interactions at doses relevant to consumer CBD use.⁵ The Dravet syndrome trial that underpins Epidyolex's medical licensing also recorded abnormal liver function tests in the CBD group.² Anyone taking regular medication, particularly blood thinners, antiepileptics, or immunosuppressants, should speak to a pharmacist or GP before starting CBD rather than assuming it is risk-free because it is sold as a food supplement.

How do I know if a CBD product I've bought is trustworthy?

Check three things. First, confirm it appears on the FSA's public list of CBD products linked to an active novel food application; anything absent or marked "Removed" falls outside the current enforcement tolerance. Second, look for a stated THC content per serving backed by a current batch-specific certificate of analysis, rather than a bare "THC-free" claim. Third, be sceptical of dosing recommendations well above the FSA's 10mg-per-day advisory maximum. A study of online CBD extracts found significant mislabeling was common, so independent lab verification, not marketing copy, is what actually confirms what is in the bottle.¹

Will CBD eventually be fully authorised in the UK?

Most likely, though the timeline keeps slipping. Three applications have already cleared the FSA's own safety assessment and been through public consultation, which is a materially more advanced position than restricted ingredients like Turkey Tail or Cordyceps militaris, neither of which has an active application moving toward authorisation at all. The remaining obstacle is procedural, aligning the FSA's position with Food Standards Scotland's separate review, rather than any outstanding safety concern. Both regulators have pointed to autumn 2026 as a plausible window for a decision, but that date has already moved once and is not guaranteed.

Conclusion

CBD occupies an unusual position in UK food regulation: a mainstream, widely sold product that has never actually cleared the legal bar required to sell it. That is not because of any adverse safety finding. It is because the novel food authorisation process is slow, and aligning a GB-wide decision across four nations has repeatedly pushed the finish line back.

CBD is legal, mainstream, and available everywhere in the UK, from pharmacies to supermarkets to Amazon; buying it isn't in question. What's still pending is the formal food-safety authorisation, so a shop shelf or marketplace listing reflects official tolerance rather than a completed regulatory sign-off. Checking the FSA's public list, insisting on a real certificate of analysis, and keeping intake within the 10mg-per-day advisory ceiling are the three checks that actually matter. If you'd rather sidestep the novel food question entirely, Ashwagandha, L-Theanine, and Magnesium Glycinate target similar ground without it.

For the current legal status of medicinal mushrooms facing similar restrictions, see our UK Novel Food Tracker.